Novo Nordisk to invest 5.6 billion euros to meet demand for treatments against diabetes and obesity

A massive investment. The Danish laboratory Novo Nordisk, known in particular for its antidiabetic Ozempic, will invest 42 billion crowns (5.6 billion euros) to expand its facilities in order to meet the increase in demand for treatments against diabetes and obesity, he announced this Friday. The Danish giant, Europe's largest market capitalization, said the investment would be used to "expand existing manufacturing facilities in Kalundborg, Denmark, for the current and future product portfolio for serious chronic diseases."

“This investment will create additional capacity across the entire global value chain, from active pharmaceutical ingredient (API) manufacturing to packaging, with the vast majority invested in API capacity,” Novo said Nordisk in a press release. A new “multi-product facility” will also be built and the investment is expected to lead to the creation of 800 new jobs, 700 in the new API plant and 100 in a new packaging plant, he highlighted.

Novo Nordisk saw its results jump thanks to the success of its anti-diabetic and anti-obesity treatments, Ozempic and Wegovy. Over the first nine months of the year, turnover rose 33% to 166.4 billion crowns, with a 58% jump in Ozempic's sales and a 492% jump in those of Wegovy. An injectable antidiabetic drug, Ozempic is very popular on social networks for its weight-loss properties, even though it is not indicated for medical purposes. Wegovy is a treatment for obesity launched in the United States two years ago and marketed only in Denmark, Norway, the United Kingdom and Germany.